Carnitine palmitoyl transferase-1A (CPT1A): A new tumor specific target in human breast cancer

Oncotarget

Volumn 7, Issue 15, 2016, Pages 19982-19996

  Pucci, Sabina ^a   Zonetti, Maria Josè ^a   Fisco, Tommaso ^a   Polidoro, Chiara ^a   Bocchinfuso, Gianfranco ^a   Palleschi, Antonio ^a   Novelli, Giuseppe ^a   Spagnoli, Luigi G ^a   Mazzarelli, Paola ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Breast cancer; Carnitine palmitoyl transferase 1A; HDAC inhibitor; Tumor metabolism; Tumor specific target

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; CASPASE 3; CASPASE 9; HISTONE DEACETYLASE 1; PLATELET DERIVED GROWTH FACTOR A; PROTEIN BAD; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1A, HUMAN; HDAC1 PROTEIN, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; BAD GENE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CASP9 GENE; CELL VIABILITY; COL18A1 GENE; CONTROLLED STUDY; CPT1A2 GENE; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; PDGF A GENE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SERPINB2 GENE; TIMP 1 GENE; TUMOR INVASION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR DYNAMICS; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARNITINE O-PALMITOYLTRANSFERASE; CELL PROLIFERATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HUMANS; MOLECULAR DYNAMICS SIMULATION; OXIDATION-REDUCTION; TUMOR CELLS, CULTURED;

EID: 84964714873     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6964     Document Type: Article

References (39)

1. Britton CH, Schultz RA, Zhang B, Esser V, Foster DW and McGarry JD. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci USA. 1995; 92:1984-8.
2. Weis BC, Esser V, Foster DW, McGarry JD. Rat heart expresses two forms of mitochondrial carnitine palmitoyltransferase I. The minor component is identical to the liver enzyme. J Biol Chem. 1994; 269:18712-5.
3. Sierra AY, Grataco E, Carrasco P, Clotet J, Ureña J, Serra D, Asins G, Hegardt FG, Casals N. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem. 2008; 283:6878-6885.
4. Lopez-Vinas E, Bentebibel A, Gurunathan C, Morillas M, de Arriaga D, Serra D, Asins G, Hegardt FG, Gómez-Puertas P. Definition by functional and structural analysis of two malonyl-CoA sites in carnitine palmitoyltransferase 1A. J Biol Chem. 2007; 282:18212-18224.
5. Mazzarelli P, Pucci S, Bonanno E, Sesti F, Calvani M, Spagnoli LG. Carnitine palmitoyltransferase I in human carcinomas: a novel Role in histone deacetylation? Cancer Biol Ther. 2007; 6:1606-13.
6. Lopez Rodas G, Brosch G, Georgieva EI, Sendra R, Franco L, Loidl P. Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin. FEBS Lett. 1993;317: 175-80.
7. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol. Oncol. 2012; 6:579-589.
8. Connolly R, Stearns V. Epigenetics as a Therapeutic Target in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia. 2012; 7:191-204.
9. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004; 112:171-8.
10. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008; 3:28-37.
11. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23:3923-31.
12. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005; 23:3912-22.
13. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008; 19:4062-75.
14. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS, Yu Y. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer. 2007; 120:1664-8.
15. Pieper U, Eswar N, Webb BM, Eramian D, Kelly L, Barkan DT, Carter H, Mankoo P, Karchin R, Marti-Renom MA, Davis FP, Sali A. MODBASE, a database of annotated comparative protein structure models and associated resources. Nucl Acids Res. 2009; 37:D347-D354.
16. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucl Acids Res. 2003; 31:3381-5.
17. Guex N, Peitsc MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997; 18:2714-2723.
18. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. Protein structure homology modeling using SWISS-MODEL workspace. Nature Protocols. 2009; 4:1-14.
19. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucl Acids Res. 2005; 33:W363-367.
20. Andrusier N, Nussinov R, Wolfson HJ. FireDock: fast interaction refinement in molecular docking. Proteins. 2007; 69:139-159.
21. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph. 1996; 14:51-55.
22. Van Gunsteren WF, Billeter SR, Eising AA. Biomolecular Simulation. In: Hochschulverlag AG, ed. The GROMOS96 Manual and User Guide. ETH Zurich Press Publishing. 1996.
23. Martinelli S, Torreri P, Tinti M, Stella L, Bocchinfuso G, Flex E, Grottesi A, Ceccarini M, Palleschi A, Cesareni G, Castagnoli L, Petrucci TC, Gelb BD, et al. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet. 2008; 17:2018-2029.
24. Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984; 81:3684-369.
25. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh ewald potential. J. Chem. Phys. 1995; 103:8577-8592.
26. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 2007; 35:W522-5.
27. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol. 1997; 112:535-542.
28. Vajda S, Kozakov D. Convergence and combination of methods in protein-protein docking. Curr Opinion Struct Biol. 2009; 19:164-170.
29. Bocchinfuso G, Stella L, Martinelli S, Flex E, Carta C, Pantaleoni F, Pispisa B, Venanzi M, Tartaglia M, Palleschi A. Structural and Functional Effects of Disease-Causing Amino Acid Substitutions Affecting Residues Ala72 and Glu76 of the Protein Tyrosine Phosphatase SHP-2. Proteins. 2007; 66:963-974.
30. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt IV, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, et al. Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease. Am. J. Hum. Genet. 2006; 78:279-290.
31. Palleschi A, Coviello T, Bocchinfuso G, Alhaique F. Investigation on a New Scleroglucan/borax Hydrogel: Structure and Drug Release. International Journal of Pharmaceutics. 2006; 322:13-21.
32. Fernando RI, Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell. 2004; 15:3266-84.
33. Clerkin JS, Naughton R, Quiney C, Cotter TG. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Letters. 2008; 266:30-36.
34. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88:277-85.
35. Tonnetti L, Netzel-Arnett S, Darnell GA, Hayes T, Buzza MS, Anglin IE, Suhrbier A, Antalis TM. SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. Cancer Res. 2008; 68:5648-57.
36. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005; 7:R788-95.
37. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brünner N, Klijn JG, Offenberg H, Foekens JA. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem. 2007; 53:1280-8.
38. Davis T, Kennedy C, Chiew YE, Clarke CL, DeFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in mammary epithelial cells. Clin Cancer Res. 2000; 6:4334-42.
39. Liu XS, Little JB, Yuan ZM. Glycolytic metabolism influences global chromatin structure. Oncotarget. 2015; 6:4214-25. doi: 10.18632/oncotarget.2929.